Lawmakers have confirmed that they will demand the relocation of the European Medicines Agency from its current base in London when the UK exits the European Union.
A vote in the European Parliament set the mandate for negotiators, establishing that retaining the EMA in an EU member state will be a red line in the discussions.
The European medicinal product regulator, which has been based in London since its inception in 1995, has just settled into a 25-year lease on a new premises in the prestigious Canary Wharf area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze